ADCT
ADC Therapeutics SANYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$466.25M
P/E Ratio
—
EPS
$-1.12
Beta
1.95
52W High
$4.98
52W Low
$1.05
50-Day MA
$4.02
200-Day MA
$3.68
Dividend Yield
—
Profit Margin
-175.30%
Forward P/E
—
PEG Ratio
—
About ADC Therapeutics SA
ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.
Fundamentals
| Revenue (TTM) | $81.36M |
| Gross Profit (TTM) | $-26.16M |
| EBITDA | $-105.39M |
| Operating Margin | -69.30% |
| Return on Equity | -706.00% |
| Return on Assets | -20.60% |
| Revenue/Share (TTM) | $0.64 |
| Book Value | $-1.48 |
| Price-to-Book | 3.42 |
| Price-to-Sales (TTM) | 5.73 |
| EV/Revenue | 4.129 |
| EV/EBITDA | -1.43 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 36.40% |
| Shares Outstanding | $127.04M |
| Float | $100.86M |
| % Insiders | 12.92% |
| % Institutions | 68.85% |
Analyst Ratings
Consensus ($8.20 target)
1
Strong Buy5
BuyData last updated: 4/7/2026